An Aspen Pharmacare emblem is seen at outdoors firm places of work in Woodmead, Johannesburg, South Africa, September 13, 2018. REUTERS/Siphiwe Sibeko/File Photograph
GQEBERHA, South Africa, Oct 25 (Reuters) – South Africa’s Aspen Pharmacare (APNJ.J) is aiming to ramp up its COVID-19 vaccine manufacturing capability to 1.3 billion doses a yr by February 2024, up from annual output of round 250 million doses now, the corporate’s CEO instructed Reuters.
Aspen is doing the ultimate phases of producing for Johnson & Johnson’s (JNJ.N) COVID-19 vaccine in a so-called “fill and end” deal, however CEO Stephen Saad stated in an interview that the businesses had been near asserting a broader deal for Aspen to provide Johnson & Johnson’s COVID-19 shot beneath licence.
Reporting by Promit Mukherjee
Writing by Alexander Successful; Modifying by Jon Boyle
Our Requirements: The Thomson Reuters Trust Principles.
0 Comments